Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivaglobin in previously untreated patients with primary immunodeficiency
2006-006522-25Phase 4Completed
- Sponsor
- CSL Behring
- Start
- Dec 2006
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyvalent human immunoglobulin in common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA) and Immunogenetic disorder, sponsored by CSL Behring. Primary endpoint: Serum IgG trough level on Day 12. Started Dec 2006; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
common variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)Immunogenetic disorder
Beyond the preview
Go deeper on 2006-006522-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006522-25.